.jpeg)
2026-04-13 07:05:12
Anagrelide is a platelet-lowering agent used in essential thrombocythemia (ET). Learn about its indications, mechanism, potential side effects, and expert guidance for safe use in managing elevated platelet counts.
2026-04-13 04:04:58
A comprehensive overview of Azacitidine (Azacitidine) for Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelomonocytic Leukemia (CMML). Learn about indications, legal purchase options, and essential precautions for patients seeking cross-border medication access.
2026-04-07 03:22:33
The clinical medication regimen of Avatrombopag (brand name Doptelet) 20mg specification, details the initial dose, adjustment rules and personalized medication principles for immune thrombocytopenia and chronic liver disease-related thrombocytopenia, to provide professional reference for clinical safe medication.
2026-04-07 02:55:19
This article explains the core pharmacological mechanism of Gilteritinib (brand name Xospata) in the treatment of FLT3-mutated acute myeloid leukemia (AML), and sorts out the relevant impacts of drug discontinuation on disease control and clinical outcomes, to provide professional reference for clinical medication decision-making.
2026-04-03 07:03:54
Avatrombopag (brand name Doptelet) and Hetrombopag are both oral thrombopoietin (TPO) receptor agonists, core treatments for thrombocytopenia. While sharing a homologous mechanism of action, they have clear differences in molecular structure, global indication coverage, clinical application scenarios, and pharmacokinetic profiles. This article explains their key distinctions and clinical selection logic.
2026-04-01 02:55:09
On April 1, 2026, the U.S. FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), indicated for pediatric patients with biallelic ITGB2 variants and no available HLA-matched sibling donor for allogeneic hematopoietic stem cell transplantation.
2026-03-24 04:27:54
Pegcetacoplan is a complement C3 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) treatment. This article details injection reactions, infection risks and monitoring points to help patients use medication safely.
2026-03-20 03:20:58
Pegcetacoplan is a PEGylated complement C3 inhibitor used for treating adult paroxysmal nocturnal hemoglobinuria, providing comprehensive control of complement-mediated hemolytic reactions.
2026-03-19 04:04:05
Eltrombopag is a novel oral TPO receptor agonist that stimulates bone marrow megakaryocytes to promote platelet production, providing non-immunosuppressive treatment options for patients with immune thrombocytopenia and aplastic anemia.
2026-03-17 06:58:36
MDS targeted drugs are not chemotherapy; they are precision treatments targeting specific molecular markers. This article details the mechanistic differences, the critical role of genetic testing, side effect comparisons, and personalized strategies for children, the elderly, and patients with comorbidities.
2026-03-13 07:08:13
Enasidenib is the first approved oral IDH2 inhibitor, brand name Idhifa, designed for patients with relapsed or refractory acute myeloid leukemia carrying IDH2 mutations. This article details mechanism of action, indications, dosage and adverse reaction management.
2026-03-13 05:38:15
Anagrelide is an oral platelet production inhibitor for treating essential thrombocythemia. This article covers indications, recommended dosage, administration methods, efficacy monitoring and common side effects for safe medication use.
